CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB

Deregulation of the cyclin-dependent kinases (CDK) 4 and 6 (cdk4/6)–cyclin D-INK4—retinoblastoma protein (Rb) signaling pathway is among the most common aberrations found in glioblastoma (GBM) with more than 80% of patients estimated to be affected. We conducted an open label, multi-center, phase II...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Lee, Eudocia, Muzikansky, Alona, Arrillaga-Romany, Isabel, Chukwueke, Ugonma, Cloughesy, Timothy, Colman, Howard, Daras, Mariza, de Groot, John, Mcfaline-Figueroa, Jose, Nayak, Lakshmi, Prins, Robert, Reardon, David, Taylor, Jennie, Ligon, Keith, Wen, Patrick
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Clinical Trials: Non-Immunologic
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651046/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.213
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires